Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

IDH1 p.R132H ctDNA and D-2-hydroxyglutarate as CSF biomarkers in patients with IDH-mutant gliomas.

Journal of neuro-oncology - 1 Sept 2022

Fujita Yoko, Nunez-Rubiano Luis, Dono Antonio, Bellman Allison, Shah Mauli, Rodriguez Juan C, Putluri Vasanta, Kamal Abu Hena Mostafa, Putluri Nagireddy, Riascos Roy F, Zhu Jay-Jiguang, Esquenazi Yoshua, Ballester Leomar Y

Abstract excerpt

INTRODUCTION: We aimed to evaluate IDH1 p.R132H mutation and 2-hydroxyglutarate (2HG) in cerebrospinal fluid (CSF) as biomarkers for patients with IDH-mutant gliomas. METHODS: CSF was collected from patients with infiltrating glioma, and 2HG levels were measured by liquid chromatography-mass spectrometry. IDH1 p.R132H mutant allele frequency (MAF) in CSF-ctDNA was measured by digital droplet PCR (ddPCR). Tumor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Circulating Tumor DNA

Share to Glioma

Share to Glioma Diagnosis and Treatment

Share to Glutarates

Share to Isocitrate Dehydrogenase

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 35816267
DOI: 10.1007/s11060-022-04060-1
PMCID: PMC10183250

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

IDH1 p.R132H ctDNA and D-2-hydroxyglutarate as CSF biomarkers in patients with IDH-mutant gliomas.PMID 35816267Read ↗

Minimally Invasive Detection of IDH1 Mutation With Cell-Free Circulating Tumor DNA and D-2-Hydroxyglutarate, D/L-2-Hydroxyglutarate Ratio in Gliomas.Semantic proximity Read ↗

Cerebrospinal fluid D-2-hydroxyglutarate for IDH-mutant glioma: utility for detection versus monitoringSemantic proximity Read ↗

Cerebrospinal fluid 2-hydroxyglutarate as a monitoring biomarker for IDH-mutant gliomasSemantic proximity Read ↗

Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with isocitrate dehydrogenase-mutated glioma.Semantic proximity Read ↗

Detection of IDH1 mutation in the plasma of patients with glioma.Semantic proximity Read ↗

The clinical use of IDH1 and IDH2 mutations in gliomasSemantic proximity Read ↗

Clinical utility of a blood based assay for the detection of IDH1.R132H-mutant gliomas.Semantic proximity Read ↗

Selective Detection of the D-enantiomer of 2-Hydroxyglutarate in the CSF of Glioma Patients with Mutated Isocitrate Dehydrogenase.Semantic proximity Read ↗

In Vivo 2-Hydroxyglutarate Monitoring With Edited MR Spectroscopy for the Follow-up of IDH-Mutant Diffuse Gliomas: The IDASPE Prospective Study.Semantic proximity Read ↗

Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma.Semantic proximity Read ↗

IDH1 mutation is detectable in plasma cell-free DNA and is associated with survival outcome in glioma patients.Semantic proximity Read ↗

Tissue 2-Hydroxyglutarate and Preoperative Seizures in Patients With Diffuse Gliomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.